BioNTech: UK asked deep questions about vaccine

BioNTech's chief commercial officer, Sean Marett, told The Associated Press on Wednesday that the British authorities had asked extremely "deep questions and detailed questions" before granting the company a temporarily license for its COVID-19 vaccine.

He denied that the UK decision would divert supply from elsewhere and that the company would adhere to "fair allocation for everyone" and that he hoped the company would make a "fair profit...so we can keep in business."

BioNTech confirmed Wednesday they'd won permission for emergency use of their COVID-19 vaccine in Britain, the world's first coronavirus injection that's backed by rigorous science - and a major step toward eventually ending the pandemic.

The company said its priority now was to begin transporting the vaccine to the UK as quickly as possible.

The approval by Britain's health regulators allows the UK to become one of the first countries to begin vaccinating its population as it tries to curb Europe's deadliest outbreak.